High-dose interleukin-2 (HD IL-2) continues to have a favorable safety profile compared with data in the original package insert.
Researchers are enrolling patients for part 2 of a phase 2 trial to compare dalantercept plus axitinib for treatment of renal cell carcinoma (RCC).
There are various emerging targeted therapies in renal cell carcinoma (RCC), including cabozantinib, dalantercept plus axitinib.
Axitinib treatment may result in higher drug costs compared with everolimus.
Final overall survival results of the RECORD-3 trial are consistent with results and support the standard sequence of sunitinib followed by everolimus.
A phase 2 trial is enrolling patients with renal cell carcinoma (mRCC) to compare the combination of axitinib plus TRC105 with axitinib alone.
Axitinib initiated at 5 mg twice daily resulted in toleration of higher daily doses with sustained efficacy in patients with metastatic renal cell carcinoma (mRCC).
Similar Outcomes with Everolimus as Second Targeted Therapy for aRCC After Pazopanib or Sunitinib/SorafenibNovember 07, 2015
Clinical outcomes with everolimus as a second targeted therapy were not significantly different in advanced renal cell carcinoma (aRCC).
Side effects with immunotherapy are different from, and in most cases of PD-1 inhibition, better than chemotherapy.
A large percentage of real-world patients with metastatic renal cell carcinoma (mRCC) initially deferred systemic therapy.
Differing opinions on initial therapy for patients with metastatic renal cell carcinoma (mRCC).
In a population-based setting, sunitinib and pazopanib have similar efficacy in first-line treatment of metastatic renal cell carcinoma (mRCC).
Patients with clear cell renal cell carcinoma who experience RECIST-defined disease progression may be able to safely continue nivolumab treatment.
Clinical benefit and patient characteristics were common reasons for initial systemic therapy for patients with metastatic renal cell carcinoma (mRCC).
Third-line targeted therapy has demonstrated activity and should be offered to clinically eligible patients with metastatic renal cell carcinoma (mRCC).
Everolimus continued to add clinical benefit in the second-line setting in patients with metastatic renal cell carcinoma (mRCC).
Dose-escalation of tyrosine kinase inhibitors (TKIs) in select patients with metastatic renal cell carcinoma (mRCC) can reduce tumor burden.
There are differing opinions on whether ischemia still matters during partial nephrectomy in patients with locally advanced renal cell carcinoma.
Nuclear or molecular imaging offers a promising non-invasive means of determining renal tumor histology for the purpose pretreatment risk stratification.
There are differing opinions on whether renal mass biopsy should be used for patients with small renal masses.
The high level of variability among treatment of renal cancer could benefit from strategic quality improvement.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy